InterPAD - DETAILS

flutamide, 13311-84-7, Niftolide, Eulexin, Niftholide, niftolid, NFBA, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide, Sch 13521, Drogenil, Cebatrol, veterinary, Flutamidum, Flutamida, Flutamin, 4'-Nitro-3'-trifluoromethylisobutyranilide, Sch-13521, Ham's F-12 medium, N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE, Flutamidum [INN-Latin], 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide, Flutamida [INN-Spanish], SCH13521, Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-, CCRIS 7246, NSC 215876, alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide, EINECS 236-341-9, MFCD00072009, NSC-215876, BRN 2157663, CHEBI:5132, Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, DTXSID7032004, UNII-76W6J0943E, CHEMBL806, 76W6J0943E, 4-Nitro-3-(trifluoromethyl)isobutyranilide, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide, DTXCID9011121, Flutamide [USAN:USP:INN:BAN], NCGC00015452-09, Eulexine, Chimax, 4'-Nitro-3'-trifluoromethylisobutyramilide, Flutamidum (INN-Latin), CAS-13311-84-7, m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-, m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-, Flutamida (INN-Spanish), FLUTAMIDE (MART.), FLUTAMIDE [MART.], FLUTAMIDE (USP-RS), FLUTAMIDE [USP-RS], Flutamide USP25, FLUTAMIDE (EP IMPURITY), FLUTAMIDE [EP IMPURITY], FLUTAMIDE (EP MONOGRAPH), FLUTAMIDE [EP MONOGRAPH], FLUTAMIDE (USP MONOGRAPH), FLUTAMIDE [USP MONOGRAPH], Flutamide (USAN:USP:INN:BAN), Prostandril, Odyne, .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide, SMR000058187, Eulexin (TN), m-Propionotoluidide,.alpha.,.alpha.-trifluoro-, SR-01000075888, N-[4-Nitro-3-(trifluoromethyl)phenyl]isobutyramide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide, Flutamid, .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide, m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-, 4'-Nitro-3'-(trifluoromethyl)isobutyranilide, Flutamide,(S), Prestwick_228, Flutamide (Eulexin), NK-601, Spectrum_001210, CPD000058187, FLUTAMIDE [INN], FLUTAMIDE [JAN], FLUTAMIDE [MI], FLUTAMIDE [USAN], Prestwick0_000180, Prestwick1_000180, Prestwick2_000180, Prestwick3_000180, Spectrum2_001201, Spectrum3_001421, Spectrum4_000829, Spectrum5_001450, Lopac-F-9397, F0663, Flutamide (pubertal study), F 9397, FLUTAMIDE [WHO-DD], SCHEMBL3934, Lopac0_000557, BSPBio_000079, BSPBio_003122, KBioGR_001377, KBioSS_001690, MLS000069634, MLS001065596, MLS002548892, DivK1c_000459, SPECTRUM1500995, SPBio_000982, SPBio_002000, Flutamide (JP17/USP/INN), BPBio1_000087, GTPL6943, FLUTAMIDE [ORANGE BOOK], CHEMBL4759307, SCHEMBL12932289, HMS501G21, KBio1_000459, KBio2_001690, KBio2_004258, KBio2_006826, KBio3_002342, L02BB01, NINDS_000459, HMS1568D21, HMS1921O16, HMS2090I18, HMS2092O14, HMS2095D21, HMS2230P19, HMS3259I03, HMS3261P15, HMS3373C12, HMS3655G22, HMS3712D21, Pharmakon1600-01500995, AMY32524, BCP23006, HY-B0022, Tox21_110154, Tox21_202169, Tox21_300536, Tox21_500557, BDBM50131270, CCG-39105, NSC147834, NSC215876, NSC757817, s1908, AKOS001025465, AKOS015994751, AKOS025243203, m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-, Tox21_110154_1, AB02835, DB00499, KS-5091, LP00557, NC00451, NSC-147834, NSC-757817, SDCCGSBI-0050540.P004, IDI1_000459, NCGC00015452-01, NCGC00015452-02, NCGC00015452-03, NCGC00015452-04, NCGC00015452-05, NCGC00015452-06, NCGC00015452-07, NCGC00015452-08, NCGC00015452-10, NCGC00015452-11, NCGC00015452-12, NCGC00015452-13, NCGC00015452-14, NCGC00015452-15, NCGC00015452-16, NCGC00015452-19, NCGC00015452-20, NCGC00015452-32, NCGC00091460-01, NCGC00091460-02, NCGC00091460-03, NCGC00091460-04, NCGC00091460-05, NCGC00091460-06, NCGC00091460-07, NCGC00091460-08, NCGC00091460-09, NCGC00254495-01, NCGC00259718-01, NCGC00261242-01, AC-24192, BF166239, SY036411, SBI-0050540.P003, DB-042163, 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide, AB00052188, EU-0100557, FT-0626493, FT-0668764, NS00002675, SW196536-4, 4''-nitro-3''-trifluoromethylisobutyranilide, C07653, D00586, EN300-119548, AB00052188-09, AB00052188_10, AB00052188_11, A806562, Q418669, Q-201131, SR-01000075888-1, SR-01000075888-6, SR-01000075888-7, SR-01000075888-9, BRD-K28307902-001-05-0, Flutamide, certified reference material, TraceCERT(R), Z56755651, Flutamide, European Pharmacopoeia (EP) Reference Standard, N1-[4-nitro-3-(trifluoromethyl)phenyl]-2-methylpropanamide, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #, Flutamide, United States Pharmacopeia (USP) Reference Standard, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;Flutamide, alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide, m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-, Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard, 37209-54-4

Name	Flutamide
PubChem CID	3397
Molecular Weight	276.21g/mol
Synonyms	flutamide, 13311-84-7, Niftolide, Eulexin, Niftholide, niftolid, NFBA, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide, Sch 13521, Drogenil, Cebatrol, veterinary, Flutamidum, Flutamida, Flutamin, 4'-Nitro-3'-trifluoromethylisobutyranilide, Sch-13521, Ham's F-12 medium, N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE, Flutamidum [INN-Latin], 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide, Flutamida [INN-Spanish], SCH13521, Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-, CCRIS 7246, NSC 215876, alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide, EINECS 236-341-9, MFCD00072009, NSC-215876, BRN 2157663, CHEBI:5132, Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, DTXSID7032004, UNII-76W6J0943E, CHEMBL806, 76W6J0943E, 4-Nitro-3-(trifluoromethyl)isobutyranilide, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide, DTXCID9011121, Flutamide [USAN:USP:INN:BAN], NCGC00015452-09, Eulexine, Chimax, 4'-Nitro-3'-trifluoromethylisobutyramilide, Flutamidum (INN-Latin), CAS-13311-84-7, m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-, m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-, Flutamida (INN-Spanish), FLUTAMIDE (MART.), FLUTAMIDE [MART.], FLUTAMIDE (USP-RS), FLUTAMIDE [USP-RS], Flutamide USP25, FLUTAMIDE (EP IMPURITY), FLUTAMIDE [EP IMPURITY], FLUTAMIDE (EP MONOGRAPH), FLUTAMIDE [EP MONOGRAPH], FLUTAMIDE (USP MONOGRAPH), FLUTAMIDE [USP MONOGRAPH], Flutamide (USAN:USP:INN:BAN), Prostandril, Odyne, .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide, SMR000058187, Eulexin (TN), m-Propionotoluidide,.alpha.,.alpha.-trifluoro-, SR-01000075888, N-[4-Nitro-3-(trifluoromethyl)phenyl]isobutyramide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide, Flutamid, .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide, m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-, 4'-Nitro-3'-(trifluoromethyl)isobutyranilide, Flutamide,(S), Prestwick_228, Flutamide (Eulexin), NK-601, Spectrum_001210, CPD000058187, FLUTAMIDE [INN], FLUTAMIDE [JAN], FLUTAMIDE [MI], FLUTAMIDE [USAN], Prestwick0_000180, Prestwick1_000180, Prestwick2_000180, Prestwick3_000180, Spectrum2_001201, Spectrum3_001421, Spectrum4_000829, Spectrum5_001450, Lopac-F-9397, F0663, Flutamide (pubertal study), F 9397, FLUTAMIDE [WHO-DD], SCHEMBL3934, Lopac0_000557, BSPBio_000079, BSPBio_003122, KBioGR_001377, KBioSS_001690, MLS000069634, MLS001065596, MLS002548892, DivK1c_000459, SPECTRUM1500995, SPBio_000982, SPBio_002000, Flutamide (JP17/USP/INN), BPBio1_000087, GTPL6943, FLUTAMIDE [ORANGE BOOK], CHEMBL4759307, SCHEMBL12932289, HMS501G21, KBio1_000459, KBio2_001690, KBio2_004258, KBio2_006826, KBio3_002342, L02BB01, NINDS_000459, HMS1568D21, HMS1921O16, HMS2090I18, HMS2092O14, HMS2095D21, HMS2230P19, HMS3259I03, HMS3261P15, HMS3373C12, HMS3655G22, HMS3712D21, Pharmakon1600-01500995, AMY32524, BCP23006, HY-B0022, Tox21_110154, Tox21_202169, Tox21_300536, Tox21_500557, BDBM50131270, CCG-39105, NSC147834, NSC215876, NSC757817, s1908, AKOS001025465, AKOS015994751, AKOS025243203, m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-, Tox21_110154_1, AB02835, DB00499, KS-5091, LP00557, NC00451, NSC-147834, NSC-757817, SDCCGSBI-0050540.P004, IDI1_000459, NCGC00015452-01, NCGC00015452-02, NCGC00015452-03, NCGC00015452-04, NCGC00015452-05, NCGC00015452-06, NCGC00015452-07, NCGC00015452-08, NCGC00015452-10, NCGC00015452-11, NCGC00015452-12, NCGC00015452-13, NCGC00015452-14, NCGC00015452-15, NCGC00015452-16, NCGC00015452-19, NCGC00015452-20, NCGC00015452-32, NCGC00091460-01, NCGC00091460-02, NCGC00091460-03, NCGC00091460-04, NCGC00091460-05, NCGC00091460-06, NCGC00091460-07, NCGC00091460-08, NCGC00091460-09, NCGC00254495-01, NCGC00259718-01, NCGC00261242-01, AC-24192, BF166239, SY036411, SBI-0050540.P003, DB-042163, 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide, AB00052188, EU-0100557, FT-0626493, FT-0668764, NS00002675, SW196536-4, 4''-nitro-3''-trifluoromethylisobutyranilide, C07653, D00586, EN300-119548, AB00052188-09, AB00052188_10, AB00052188_11, A806562, Q418669, Q-201131, SR-01000075888-1, SR-01000075888-6, SR-01000075888-7, SR-01000075888-9, BRD-K28307902-001-05-0, Flutamide, certified reference material, TraceCERT(R), Z56755651, Flutamide, European Pharmacopoeia (EP) Reference Standard, N1-[4-nitro-3-(trifluoromethyl)phenyl]-2-methylpropanamide, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #, Flutamide, United States Pharmacopeia (USP) Reference Standard, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;Flutamide, alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide, m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-, Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard, 37209-54-4
Drug Type	Small molecule
Formula	C₁₁H₁₁F₃N₂O₃
SMILES	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
InChI	1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
InChIKey	MKXKFYHWDHIYRV-UHFFFAOYSA-N
CAS Number	13311-84-7
ChEMBL ID	CHEMBL806
ChEBI ID	CHEBI:5132
TTD ID	D0Y0SW
Drug Bank ID	DB00499
KEGG ID	C07653
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Resveratrol, Flutamide
Partner Name	Resveratrol
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Expression	AR	hsa367
In Vitro Model	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
Result	Resveratrol works in concert with antiandrogen flutamide to reduce the amount and activity of AR, suggesting new therapeutic strategies for the treatment of PCa.